Niagen Bioscience (NAGE) FCF Margin (2011 - 2026)

Niagen Bioscience (NAGE) has 14 years of FCF Margin data on file, last reported at 3.79% in Q1 2026.

• On a quarterly basis, FCF Margin fell 2966.0% year-over-year to 3.79% in Q1 2026; TTM through Mar 2026 was 3.39%, a 1486.0% decrease from a year earlier, with the FY2025 full-year figure at 10.43%, down 172.0% from the prior year.
• FCF Margin for Q1 2026 stood at 3.79%, down from 2.08% in the prior quarter.
• Over the last five years, FCF Margin for NAGE reached as high as 29.47% in Q4 2024 and fell as low as 41.71% in Q1 2022.
• Historically, FCF Margin has averaged 1.63% across 5 years, with a median of 2.08% in 2025.
• Across the five-year window, FCF Margin surged 5408 bps in 2023 and slumped 2966 bps in 2026, its largest moves.
• Year by year, FCF Margin stood at 1.56% in 2022, then surged by 296 bps to 3.06% in 2023, then jumped by 862 bps to 29.47% in 2024, then slumped by 93 bps to 2.08% in 2025, then plunged by 282 bps to 3.79% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 3.79% in Q1 2026, 2.08% in Q4 2025, and 10.89% in Q3 2025.